First Trust NYSE Arca Biotechnology Index Fund (FBT) is a healthcare and biotech ETF. As of October 28, 2026, ETF Copilot scores FBT 5.4 out of 10 — highest on Growth (9.8), lowest on Value (0.2). It trades at 31.9 times earnings, against its own median of 21.1. Its ten largest holdings are 36% of the fund.
What stands out in FBT's data
Tracks U.S. biotechnology sector companies focused on innovation and growth.
Has outpaced most biotech peers over the last three years — recent gains that compound a long-term holding.
A 29% annualized return over three years tops the category median of 22%. The fund pays no dividend, and its 22.9x EBITDA multiple runs above the 17.5x peer norm.
Adds a high-valuation biotech tilt to a portfolio already holding broader technology exposure.
Why did FBT move this week? It rose 2.6% in the week to October 28, 2026 — Genmab A/S and Veracyte drove it
FBT rose 2.6% in the week to October 28, 2026. The holdings that moved it most were Genmab A/S (+44.8%), Veracyte (+8.8%) and TG Therapeutics (+7.9%); Corcept Therapeutics (−25.8%) pushed the other way.
How is FBT rated? ETF Copilot scores First Trust NYSE Arca Biotechnology Index Fund (FBT) 5.4 out of 10
As of October 28, 2026, ETF Copilot scores First Trust NYSE Arca Biotechnology Index Fund (FBT) 5.4 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 5.4 / 10
- Growth: 9.8 / 10
- Value: 0.2 / 10
- Risk: 4.1 / 10
- Quality: 2.0 / 10
- Return: 7.6 / 10
Is FBT expensive right now? It trades at 31.9 times earnings, against its own median of 21.1
As of October 28, 2026, FBT is more expensive than 94% of its own last 6 years.
Trailing 12 months, built from FBT's holdings. How we calculate this →
What's inside FBT?
What's inside FBT: Size (Large 38%, Mid 49%, Small 14%); Geography (International 17%, US 83%).
What are FBT's top holdings? The ten largest are 36% of the fund
Genmab A/S, Halozyme Therapeutics, Biogen, Veracyte, Regeneron Pharmaceuticals, Exelixis, Alkermes, Amgen, Adma Biologics and United Therapeutics are FBT's largest holdings, in that order.
Less concentrated than 55% of Health & Biotech ETFs.
Half of FBT's weight sits in its 15 largest positions, and once those weights are taken into account it behaves like 30 equally weighted holdings.
What is FBT's expense ratio? 0.55% a year
As of October 28, 2026, FBT charges 0.55% a year and holds $3.0B in assets across 30 positions.
| Measure | FBT |
|---|---|
| Expense ratio | 0.55% |
| Assets under management | $3.0B |
| Holdings | 30 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “First Trust NYSE Arca Biotechnology Index Fund (FBT) scores and holdings analysis”, as of October 28, 2026.
https://etf-copilot.com/etf/fbt
ETF Copilot Pro unlocks FBT's price and what each holding weighs.
Try Pro free →